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Abstract
Background: A variety of different approaches to measuring contraceptive use have been used or proposed, either
to assess current use or adherence over time, using subjective or objective measures. This paper reports an
overview of approaches to measuring adherence to the oral contraceptive, intra-uterine device, sub-dermal implant,
and injectable and describes how we assessed contraception use in the MObile Technology for Improved Family
Planning (MOTIF) trial in Cambodia.
Main body: We summarise and discuss advantages and disadvantages of different subjective and objective
approaches to measuring adherence to the oral contraceptive, intra-uterine device, sub-dermal implant, and
injectable such as self-reports, clinic records, electronic monitoring devices, clinical examination and biomarkers.
For the MOTIF trial, we did not consider it feasible to measure objective contraception use as many participants
lived a long distance from the clinic and we were concerned whether it was appropriate to ask women to return
to clinic for a physical examination simply to verify self-report information already provided.
We aimed to assess the validity of the four-month data with 50 participants, calculating the sensitivity and
specificity of self-reported data compared with objective measurement. For the 46 valid measurements obtained,
the sensitivity and specificity was 100% for self-reported contraception use compared to objective measurement
but this study had some limitations. To assess reliability of self-report data we compared calendar data collected on
effective contraception use at months 1–4 post-abortion, collected separately at four and 12 months. Agreement
ranged from 80 to 84% with a kappa statistic ranging from 0·59 to 0·67 indicating fair to good agreement.
Conclusion: There is no perfect method of assessing contraception use and researchers designing future studies
should give consideration of what to measure, for example current use or detailed patterns of use over time, and
remain mindful of what will be feasible and acceptable to the study population. Although self-reported data on
contraception use are considered less reliable, and prone to social desirability bias, it is often the standard approach
for contraception research and provides data comparable to previous studies.
Trial registration: ClinicalTrials.gov Identifier: NCT01823861. Registered: March 30, 2013.
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Background
Contraception use can be measured for different reasons,
for example to collect information on general patterns of
contraception use over several years using Demographic
and Health Surveys, or to assess the impact of interven-
tions to improve contraception use, often focusing on spe-
cific methods, over a shorter time period. A variety of
different approaches to measuring contraceptive use have
been used or proposed, either to assess current use or ad-
herence over time, using subjective or objective measures.
This paper reports an overview of approaches to measur-
ing adherence to the oral contraceptive (OC), intra-
uterine device (IUD), sub-dermal implant, and injectable
and describes how we assessed contraception use in the
MObile Technology for Improved Family Planning
(MOTIF) trial in Cambodia [1].
Main text
Overview of measuring adherence to common
contraceptive methods
The majority of studies assessing contraception use have
relied on self-report measures, which are relatively sim-
ple and inexpensive to administer. However, concerns
about bias associated with self-report measures leading
to overestimation of contraceptive use and underestima-
tion of abortion have led to calls for increased rigor in
measuring contraception use [2–4].
For fertility surveys, contraceptive calendars, such as
those used in Demographic and Health surveys, have
been found to generate more complete and accurate
data on past self-reported contraceptive use than other
questionnaire formats [5–7]. These methods are con-
venient, inexpensive to administer and the only practical
way to obtain information on contraceptive use dating
back several years. However, in clinical trials, objective
measures are generally considered preferable to subject-
ive measures, as they are less prone to bias [8]. Table 1
summarises approaches to measuring use of different
contraceptive methods.
The oral contraceptive is probably the most challen-
ging contraceptive method to measure. The combined
oral contraceptive pill (COCP) containing oestrogen and
a progestogen is taken for 21 days, with a 7-day break,
whereas the progesterone-only pill (POP) containing one
hormone is taken continuously. One-year pregnancy
rates are estimated to be 0.3% with perfect use, but 7–
8% as commonly used [9], thus measures that assess
missed pills as well as current use are important.
No gold standard measure of OC use is available. The
ideal measure of OC would be one that is objective, can
distinguish reliably between non-users, inconsistent, and
consistent users, does not rely on a closed pharmacy sys-
tem (i.e. accounts for people obtaining contraception in
different settings); is inexpensive, feasible in different
settings, is acceptable to participants, and is applicable
to pills containing different hormones. A systematic re-
view of measurement methods for OC use found that
the majority (71%) of research studies relied solely on
self-report measures (such as interviewer or self-
administered questionnaires) rather than objective mea-
sures, and the terminology used to describe OC use
(such as “continuation”, “compliance” and “adherence”)
varied and was rarely described [10].
Objective measures of OC use include biological
markers or electronic medication monitors. Biomarkers
can either directly measure the hormones in the pill or a
proxy measure. Direct measurement of contraceptive
steroid levels (for example, Ethinylestradiol or Levonor-
gestrel) is possible, but only at specialist laboratories,
and thus for cost and logistical reasons, might not be
feasible in low-income settings. Other researchers have
proposed measurement of hepatic binding globulins,
which are increased by Ethinylestradiol (EE2). Thyroxine
Binding Globulin (TBG) and Corticosteroid Binding
Globulin (CBG) were found to distinguish noncompliant
users from compliant users [11]. In one study, riboflavin
was added to the OC as a urinary marker and assessed
by urine florescence [12]. However, the addition of a
urine marker to a pill would present significant chal-
lenges, and requires a closed pharmacy system. The
main advantage of biological measures is that they indi-
cate ingestion of the pill and are good at assessing
current use. However, disadvantages are that they are
less good at distinguishing inconsistent users from con-
sistent users [10, 13], and blood tests may not be accept-
able to study participants. It is theoretically possible to
measure EE2 in urine samples by enzyme-linked im-
munosorbent assay (ELISA), an assay developed for de-
tecting EE2 in animals for the food industry. This might
be more acceptable than a blood test, but to our know-
ledge this test has not been validated for human urine.
Electric monitoring devices (EMDs) can be used to
measure adherence to oral medication by recording when
a participant opens a pill box or blister pack. Such infor-
mation can be downloaded periodically or transmitted in
real-time. EMDs have been shown to be more accurate
than self-report measures, pill counts, and biomarkers for
examining antidepressant adherence [14], and used in low
income settings, for example to assess anti-retroviral ad-
herence in Kenya [15]. In the field of contraception, two
studies reported poorer OC adherence as measured by
electronic medication monitoring compared with self-
report measures [13, 16]. Thus, advantages of EMDs are
that they can provide more detailed information of pat-
terns of use over a period of time compared with self-
report. Limitations of EMDs are that it can be difficult to
distinguish whether interventions improve pill-taking be-
haviour or simply improve use of the monitor, that
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opening the container doesn’t equate to ingestion, and the
devices themselves could interfere with the intervention if
the participant has to transfer pills into a container.
Devices that mimic pill packets would be costly and
require a closed pharmacy system.
Measuring use of other contraceptive methods such as
implant, IUD and injectable are somewhat easier com-
pared to OC as it is not necessary to assess daily adher-
ence; the women is either protected from pregnancy by
the method, or not. These methods can be assessed as
follows. First, by self-report (i.e. asking the participant if
they are using a method) but this method is subject to
biases already mentioned. In particular it might be diffi-
cult to recall the date the method was started e.g. date
of injection. Second, objectively by reviewing clinic re-
cords, but in the case of implant and IUD, this does not
indicate continued use if the participant had the device
removed in a different clinic. Finally, current use of IUD
or implant can be assessed by clinical examination; by
palpating the sub-dermal implant or visualising the IUD
threads but this entails an intimate examination. IUD or
implant use could also be assessed by ultrasound
examination.
Assessing contraception use in the MOTIF trial
For the MOTIF trial, we did not consider it feasible to
measure objective contraception use for several reasons.
We were concerned that participants wouldn’t be able to
Table 1 Summary of approaches to measuring adherence to different contraceptive methods
Contraceptive method Measurement approach Advantages Disadvantages
Oral Contraceptive Direct observation
(clinician observes ingestion of pill)
Accurate and equates to ingestion Impractical
Self-reports (self-completed
or interview administered
questionnaire)
Simple, inexpensive and easy to
administer.
Requires training for administrators.
Subject to recall and social desirability
bias.
Clinic / pharmacy records Can help to correct poor recall.
Simple, inexpensive and objective.
Usually easy to obtain data. Can
measure at more than one point in
time.
Does not equate to ingestion and
requires a closed pharmacy system
Pill counts (individual pill or pill pack
counts)
Objective; quantifiable and easy to
perform.
However, easily altered by participant
(e.g. pill dumping), cannot assess
timing of use
Electronic Monitoring Devices Objective, precise, tracks patterns of
use over time.
Potentially expensive and may require
return visits to download data.
Participants may not adhere to using
device, intervention might improve
use of device rather than pill-taking
behaviour.
Blood hepatic binding globulin levels
(Corticosteroid Binding Globulin,
Thyroxine Binding Globulin, Lutenizing
Hormone and Sex Hormone Binding
Globulin)
Objective. Can distinguish between
consistent use and non-use
(Corticosteroid Binding Globulin and
Thyroxine Binding Globulin more
discriminating). Inexpensive compared
to measuring contraceptive steroid
level
Requires specialist laboratory. Can’t
distinguish between consistent and
inconsistent users
Blood contraceptive steroid level (e.g.
Levonorgestrel or Ethinylestradiol)
Objective, indicates indigestion. Difficult test, expensive therefore
limited potential for replication in
other studies, requires a blood test,
will not distinguish consistent from
inconsistent users
IUD / implant Self-report Simple, inexpensive and easy to
administer.
Subject to recall bias and social
desirability bias
Clinical examination or ultrasound Simple, inexpensive and easy to
administer.
Intrusive, has to be performed in clinic
setting, requires skilled personnel/
equipment
Clinic or client record Objective Requires a closed pharmacy system.
Self-held record can get lost
Injection Self-report Simple, inexpensive and easy to
administer.
Subject to recall bias and social
desirability bias.
Clinic or clinic record Objective and indicates current use Requires a closed pharmacy system.
Self-held record can get lost
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return to the clinic for objective follow-up due to
lack of time as many lived in rural areas far from the
clinic. Furthermore we were concerned about whether
it was appropriate, potentially a betrayal of trust, to ask
women to return to clinic for internal examination to
check IUD threads simply to verify self-report information
already provided. We were not able to rely on clinic re-
cords of contraception use as the trial was not operating
within a closed pharmacy system; oral and injectable con-
traceptives can be obtained from pharmacists without pre-
scriptions in Cambodia, and long-acting reversible
methods (intrauterine device or implant) could be re-
moved in other clinics. Therefore assessment of the pri-
mary outcome, use of effective contraception at four and
12 months post-abortion for the MOTIF trial was self-
report by phone call. The questionnaire was designed to
reduce social desirability bias by first asking participants
“Are you using a contraception method?” followed by
“Which method are you using?” if the women answered
“Yes” (without prompting for specific methods). We felt it
was unlikely that participants would over-report using one
particular contraception method over another e.g. IUD vs.
implant. To assess reliability of self-report data we com-
pared calendar data collected on effective contraception
use at months 1–4 post-abortion, collected separately at
four and 12 months. Agreement ranged from 80 to 84%
with a kappa statistic ranging from 0·59 to 0·67 indicating
fair to good agreement.
We aimed to assess the validity of the four-month data
with 50 participants, calculating the sensitivity and specifi-
city of self-reported data compared with objective meas-
urement (considered the gold standard) [17]. Consecutive
participants recruited from the two peri-urban clinics who
had provided self-report follow up were invited to attend
for objective assessment of contraceptive use by a research
assistant blinded to treatment allocation as follows: assess
the position of an implant or IUD (ultrasound or clinical
examination according to participant preference); self-
held record of injection within the previous three months
or permanent method; pill counts defined as > 90% of pills
taken since last prescription dispensed. Those attending
were given USD$4 for travel expenses. In order to achieve
our target of 50 face-to-face objective measurements we
attempted to contact 94 participants of contraception use;
thus achieving a 53% follow up rate (compared to self-
report follow up of 86% at four months). We were unable
to contact 18 participants. Twenty participants declined to
attend (the most common reason stated was lack of time).
Six participants agreed, but then did not attend. We ob-
tained valid measurements in 46 of 50 participants who
attended. Three participants did not bring OC with them
and one was ineligible as she had not provided self-
reported contraception data. Amongst these 46 partici-
pants, the sensitivity and specificity was 100% for self-
reported IUD, implant, injectable and OC use compared
to objective measurement (Table 2).
It is uncertain if this validity study was helpful. Whilst
the sensitivity and specificity of objectively measured
contraception was 100% in those attending follow-up, the
response rate was low and it is not clear that those who
attended were representative of the wider study popula-
tion. For example, if a participant provided inaccurate
self-report data, they might be less likely to attend for ob-
jective assessment.
Conclusion
In the MOTIF trial, use of self-report measures resulted
in higher rates of follow up compared to attempts at ob-
jective measures. Self-report measures showed fair/good
reliability and the validity study did not identify any
cases of misclassification. However, the method for veri-
fying self-reported OC use by pill counts was also prone
to detection bias.
There is no perfect method of assessing contraception
use and researchers designing future studies should give
consideration of what to measure, for example current use
or detailed patterns of use over time, and remain mindful
of what will be feasible and acceptable to the study popu-
lation. For OC use, researchers should consider using the
definitions of ‘continuation’, ‘discontinuation’, ‘interrupted
use’ and ‘missed pills’ as recommended by Hall et al. [10].
Objective measures using clinic records or electronic
medication monitors might be possible if there is a
closed pharmacy system. EMDs linked to mobile devices
providing real-time data on pill taking will provide the
most detailed information on OC use. Biological mea-
sures or clinical examination might be feasible if partici-
pants are willing and able to return to the clinic, and
there is laboratory capacity. Self-report measures can be
optimised by careful consideration of questions to avoid
Table 2 Objective vs. self-report follow up at four months
Self-report
(number)
Objective measurement
(number)
Current contraception use
Intra-uterine device 11 11
Implant 4 4
Injectable 3 3
Oral contraceptive 9 9
No method/non-effective
method
19 19
Total effective 27 27
Total no/non-effective method 19 19
Total measurements included
in analysis
46 46
Amongst the 46 participants the sensitivity of self-report data compared to ob-
jective measurement (gold standard) was 100% (27/27*100) and the specificity
was 100% (19/19*100)
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response-style bias. Although self-reported data on
contraception use are considered less reliable, and prone
to social desirability bias, it is often the standard ap-
proach for contraception research and provides data
comparable to previous studies [2, 10]. A validity study
could be considered to verify self-report measures. Future
research could explore the possibility of a urine EE2 assay
as an alternative to a blood test to distinguish between
users and non-users of OC.
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